Search Results for: "Clinic Roundup"
-
Clinic Roundup
The three clinical trials involve four of the top-ranked eye hospitals in the U.S., and two of the leading eye hospitals in the UK...The clinical trial, called Transplantation In Myocardial Infarction Evaluation (TIME), was designed to see if heart function would improve by administering stem cells derived from the patient's own bone marrow either three or seven days after a heart attackBioWorld Today | Monday, November 12, 2012 -
Pharma: Clinic Roundup
Sanofi Pasteur, of Swiftwater, Pa., the vaccines division of Sanofi SA, said Pediatric Infectious Disease Journal published pivotal clinical trial data used by the FDA to support the license expansion for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine), to include a two-dose schedule for infants and toddlers 9 months through 23 months of ageBioWorld Today | Friday, November 9, 2012 -
Clinic Roundup
Senesco Technologies Inc., of Bridgewater, N.J., said it expanded its clinical trial of SNS01-T to include diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) patientsBioWorld Today | Thursday, November 8, 2012 -
Clinic Roundup
Data were presented at the Clinical Trials on Alzheimer's Disease Meeting in Monte Carlo, MonacoBioWorld Today | Thursday, November 1, 2012 -
Clinic Roundup
Cytori Therapeutics Inc., of San Diego, said two independent investigator-sponsored and funded cell therapy clinical trials in Japan have been approved...GenSpera Inc., of San Antonio, said its lead drug, G-202, was selected by the Statewide Clinical Trials Network of Texas (CTNeT) for evaluation in a Phase II trial in patients with hepatocellular carcinomaBioWorld Today | Friday, October 26, 2012 -
Clinic Roundup
Hadasit Bio-Holdings Ltd., of Jerusalem, said portfolio company Enlivex completed a 13-patient clinical trial of cellular treatment ApoCell for graft-vs.-host disease (GvHD), with results indicating efficacy and safety in recipients of bone marrow transplants from foreign donorsBioWorld Today | Thursday, October 25, 2012 -
Clinic Roundup
Acorda Therapeutics Inc., of Ardsley, N.Y., reported safety data from more than 62,400 people with multiple sclerosis (MS) taking Ampyra (dalfampridine) extended-release tablets during the first two years of availability in the U.S., with results showing a similar safety profile as observed in clinical trialsBioWorld Today | Wednesday, October 10, 2012 -
Clinic Roundup
Neuralstem Inc., of Rockville, Md., gained the go-ahead to start a clinical trial in motor deficits due to ischemic stroke with its spinal cord stem cells (NSI-566) at BaYi Brain Hospital in Beijing, through its subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Co. LtdBioWorld Today | Friday, September 28, 2012 -
Clinic Roundup
Cellceutix Corp., of Beverly, Mass., said that it expects to start clinical trials with its anti-cancer drug Kevetrin in about three weeks at Harvard Cancer Center's Dana-Farber Cancer Institute and the Beth Israel Deaconess Medical Center...That follows institutional review board approval of an amended trial protocol, and hospital preparations are now under way at the respective institutions to allow for the commencement of the clinical trialsBioWorld Today | Tuesday, September 25, 2012 -
Clinic Roundup
ViroPharma Inc., of Exton, Pa., and Halozyme Therapeutics Inc., of San Diego, said the FDA provided guidance enabling ViroPharma to resume clinical trials testing the subcutaneous administration of hereditary angioedema drug Cinryze (C1 esterase inhibitor [human]) in combination with Halozyme's recombinant human hyaluronidase (rHuPH20BioWorld Today | Monday, September 24, 2012 -
Clinic Roundup
Imprimis Pharmaceuticals Inc., of Solana Beach, Calif., said it started a clinical trial testing Impracor, a topical cream designed to deliver ketoprofenBioWorld Today | Thursday, September 20, 2012 -
Clinic Roundup
Aeras, of Rockville, Md., and the Infectious Disease Research Institute (IDRI) said they started a clinical trial of IDRI's tuberculosis vaccine candidate, ID93 + GLA-SE...Pacific Therapeutics Ltd., of Vancouver, British Columbia, said it completed enrollment and initial dosing in its first clinical trial testing PTL-202 in healthy volunteersBioWorld Today | Friday, August 24, 2012 -
Clinic Roundup
If approved, the product, indicated for the treatment of autoimmune and inflammatory diseases, will enter clinical trialsBioWorld Today | Friday, August 17, 2012 -
Clinic Roundup
Immatics biotechnologies GmbH, of Tübingen, Germany, published data from two clinical trials of IMA901, a cancer vaccine candidate, showing that patients experience longer survival times when their immune system responds to more than one of the peptides in the vaccineBioWorld Today | Tuesday, July 31, 2012 -
Clinic Roundup
Infectex, of Moscow, said it received approval from the Russian Ministry of Health to begin a pivotal clinical trial for antibiotic SQ109 in multidrug-resistant tuberculosis (MDR-TB) patients at TB centers in three major Russian cities (Moscow, Saint Petersburg and EkaterinburgBioWorld Today | Friday, July 27, 2012 -
Clinic Roundup
BHR Pharma LLC, of Phoenix, said it reached its SyNAPSe clinical trial enrollment midpoint of 590 patients...ICT-121 is the second dendritic-cell-based vaccine to enter clinical trialsBioWorld Today | Thursday, July 26, 2012 -
Clinic Roundup
Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said Phase IIa ocular safety results published in the American Journal of Ophthalmology showed that CPP-109 (vigabatrin), a GABA aminotransferase inactivator in clinical trials to treat cocaine addiction, did not cause a decrease in visual acuity or significant peripheral visual field changes with short-term useBioWorld Today | Friday, June 29, 2012 -
Clinic Roundup
In addition to clearance to proceed with clinical trials, the company also received approval of the protocol from the institutional review board and scientific review committeeBioWorld Today | Wednesday, June 27, 2012 -
Clinic Roundup
Oncolytics Biotech Inc., of Calgary, Alberta, said that it entered an agreement with the NCIC Clinical Trials Group at Queen's University, Kingston, Ontario, which will sponsor and conduct a randomized Phase II study of Reolysin in patients with advanced or metastatic breast cancerBioWorld Today | Friday, June 22, 2012 -
Clinic Roundup
Bristol-Myers Squibb Co., of New York, formed a strategic partnership with Emory University in Atlanta to conduct clinical trials involving the pharma's investigational compoundsBioWorld Today | Thursday, June 21, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.